Stock AnalizBiocryst Pharmaceuticals Inc. BCRX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 1994 · data as of November 13, 2026
Biocryst Pharmaceuticals Inc. (BCRX) is a healthcare company listed in the US with a market value of about $2.0B. In the twelve months to September 30, 2026 it had revenue of $962M and net income of -$360M, a net margin of -37.4%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is shareholder returns (0/5).
Key numbers: a price to free cash flow of 5.4, 5-year revenue growth of 118% a year, a 5-year average ROIC of -71%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 64% below the current price.
Score: 1.6 / 5
Checks passed
- P/FCF below 20
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $962M | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M |
| Net income | -$360M | $264M | -$89M | -$227M | -$247M | -$184M | -$183M | -$109M | -$101M | -$66M | -$55M |
| Free cash flow | $366M | $345M | -$53M | -$97M | -$163M | -$145M | -$136M | -$90M | -$93M | -$41M | -$59M |
| EPS (diluted) | $-1.41 | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-940.00 | $-980.00 | $-780.00 | $-750.00 |
| Net margin | -37.4% | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | -261.2% | -209.2% |
| ROIC | — | — | — | — | — | -70.6% | -129.0% | -112.7% | -93.9% | -40.3% | -128.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $20.45, 169% above the current price; targets range from $11.00 to $32.00; the consensus rating is “Buy”; expected EPS is $0.86 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Biocryst Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 64% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Biocryst Pharmaceuticals pay a dividend?
Not currently.
Is Biocryst Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Biocryst Pharmaceuticals scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.